New platform for therapeutic antibodies: launching of the IMABGEN Platform project, an innovative service for the generation of therapeutic antibodies

December 16, 2021

CALIXAR, Biotem and the CNRS/Université Claude Bernard Lyon 1 have been granted among the laureates of the 2021 “R&D Booster” program supported by the Region Auvergne-Rhône-Alpes and Bpifrance.The partners will design and set up a native membrane antigens platform named IMABGEN for the discovery and the development of conformational monoclonal antibodies especially for immunotherapies.CALIXAR will bring to the IMABGEN consortium its proprietary technologies to isolate and produce native and functional membrane antigens (GPCRs, receptors, transporters, enzymes, …).

Share this post

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.